Trials / No Longer Available
No Longer AvailableNCT02973620
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Expanded Access Protocol; Intermediate Size Protocol: Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure Who Are Refractory to Standard Therapy
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Tenax Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levosimendan | levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours |
Timeline
- First posted
- 2016-11-25
- Last updated
- 2018-05-16
Source: ClinicalTrials.gov record NCT02973620. Inclusion in this directory is not an endorsement.